Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A phase 3 trial found that lumateperone (Caplyta) significantly reduced acute manic symptoms in bipolar I patients within just 3 days — and the benefits lasted through 3 weeks. With low dropout rates and a clean safety profile, the drug could fill a major gap in bipolar mania treatment, where few new options have emerged in two decades.
A new treatment option for bipolar I mania is showing impressive speed
A phase 3, randomized, double-blind trial presented at Psych Congress 2026 found that lumateperone (Caplyta; Johnson & Johnson) significantly reduced acute manic symptoms in hospitalized bipolar I patients in as little as 3 days — with improvements sustained through the full 22-day treatment period. The study enrolled 354 patients, who received either 42 mg of lumateperone daily or placebo.
The drug already holds FDA approval for schizophrenia and bipolar depression, but this trial (Study 451) is the first phase 3 data evaluating it specifically for acute mania — a condition that can escalate rapidly and often requires hospitalization.
By the Numbers
Why it matters: Acute mania can derail lives quickly — affecting safety, relationships, and careers. With few new bipolar mania treatments approved in the past 20 years, lumateperone's rapid onset, sustained effect, and favorable tolerability profile could meaningfully expand options for clinicians and patients alike. A second phase 3 trial (Study 452) is ongoing.
